Healthcare >> CEO Interviews >> November 18, 2002
GAIL J. MADERIS is President of Genzyme Molecular Oncology. With
more than 15 years of management experience in biotechnology and
healthcare environments, Ms. Maderis possesses a diverse
portfolio of knowledge and skills in business management,
research and development, and gene therapy. In 1997, Ms. Maderis
conceived and created Genzyme Molecular Oncology, one of Genzyme
Corporation's three tracking stock divisions, which focuses on
the development and commercialization of innovative therapeutics
to treat cancer. During the process of creating the division, Ms.
Maderis managed Genzyme's acquisition of PharmaGenics, Inc., and
initiated the major partnerships that became the cornerstone of
the business. Under her leadership, Genzyme Molecular Oncology
has signed more than a dozen commercial agreements with
pharmaceutical companies for use of its proprietary SAGE
differential gene expression technology. The division also has
formed business partnerships with world-class companies such as
Purdue Pharma and the pharmaceutical division of Kirin Brewery,
Japan. Additionally, it collaborates with several prominent
academic and research organizations including the National Cancer
Institute, The Johns Hopkins University, Dana-Farber Cancer
Institute and Massachusetts General Hospital. Prior to forming
Genzyme Molecular Oncology, Ms. Maderis was Vice President and
Business Manager of Genzyme Corporation's cystic fibrosis and
gene therapy programs. Prior to joining Genzyme, Ms. Maderis
spent seven years as a Manager at Bain & Company, Inc., where she
was responsible for developing and implementing major strategic
programs for several large companies in the pharmaceutical and
healthcare industries. She earned a Bachelor's degree with honors
in Business Administration from the University of California,
Berkeley in 1978 and received an MBA from Harvard Business School
in 1985. Profile
of Genzyme Molecular Oncology and then tell us the most important
things that have happened within the last year?
Ms. Maderis:
